Royal Fund Management’s Avanos Medical AVNS Stock Holding History

Royal Fund Management’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4	Closed	–	–	588
2018 Q4	$0	Buy	+4	New	+$210	﹤0.01%	575

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Fund Management's AVNS Position: Q1 2019 in Review

Royal Fund Management sold out of Avanos Medical (AVNS) in Q1 2019, closing a stake of 4 shares.

Royal Fund Management first reported a position in AVNS in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 338 funds tracked by Wall St. Rank hold AVNS as of Q1 2019.

Royal Fund Management reported no remaining Avanos Medical position as of Q1 2019 after selling out during the quarter.
Royal Fund Management sold 4 Avanos Medical shares in Q1 2019.
Royal Fund Management first reported a position in Avanos Medical in Q4 2018 and held it in 1 quarter.
Royal Fund Management's Avanos Medical position peaked at $0 in Q4 2018.
338 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2019.

Based on Royal Fund Management's 13F filing for Q1 2019, filed 11 May 2020.